-

06:42:17 PM

LIVE Real Time EIGR Stock Market News

EIGR - Eiger BioPharmaceuticals Inc

05/06/21 4:01 PM

Nasdaq : EIGR

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its first quarter 2021 financial

RHEA-AI

neutral

05/03/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Peginterferon Lambda

RHEA-AI

neutral

04/29/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a

RHEA-AI

neutral

04/22/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Kim Sablich to its

RHEA-AI

neutral

03/09/21 4:05 PM

Nasdaq : EIGR

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results

RHEA-AI

neutral

02/23/21 8:00 AM

Nasdaq : EIGR

Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism

Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that positive results

RHEA-AI

neutral

02/08/21 8:00 AM

Nasdaq : EIGR

Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that final results from the

RHEA-AI

neutral

01/25/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and

RHEA-AI

neutral

01/07/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress across its

RHEA-AI

very positive

11/25/20 8:42 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy (TM)

RHEA-AI

positive